» Articles » PMID: 15602722

Clinical and Virological Characteristics of Untreated Patients with Chronic Hepatitis C Who Develop Serum Alanine Aminotransferase Flare-up

Abstract

Among patients with chronic hepatitis C virus (HCV) infection, serum alanine aminotransferase (ALT) rarely increases above 500 IU/L. We examined the clinical and virological features of untreated patients with serum ALT > or = 500 IU/L. One thousand seven hundred and sixty adult patients with chronic HCV infection were followed-up. Among these patients, 22 developed ALT flare-up (M:F=13:9, median age, 50.5 years). We evaluated liver function tests, genotype, and viral titer in these patients and 44 randomly selected age- and sex-matched control without ALT flare-up. In four patients with ALT flare-up, we examined changes in viral loads and sequential changes in amino acid sequences of the core region, hypervariable region 1 (HVR1), and interferon sensitivity determining region (ISDR) before and after ALT flare-up. Multivariate analysis identified genotype 2 as the only significant determinant of ALT flare-up. ALT flare-up occurred in three of four patients without increase in viral load. Several alterations in amino acids were noted in HVR1 before and within 6 months of ALT flare-up. One or two alterations in the core region and many alterations in HVR1 were noted after ALT flare-up in some patients. Genotype 2 is an important factor for ALT flare-up. However, we could not directly relate ALT flare-up to these alterations in amino acids of the core region, HVR1, and ISDR.

Citing Articles

The Real-World Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C in Patients Active Malignancies.

Dabrowska M, Jaroszewicz J, Sitko M, Janocha-Litwin J, Zarebska-Michaluk D, Janczewska E Cancers (Basel). 2024; 16(17).

PMID: 39272972 PMC: 11394372. DOI: 10.3390/cancers16173114.


Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare.

Kanda T, Matsumoto N, Ishii T, Arima S, Shibuya S, Honda M Viruses. 2023; 15(1).

PMID: 36680223 PMC: 9861769. DOI: 10.3390/v15010183.


Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy.

Lee H, Bae S, Jang B, Hwang S, Yang H, Nam H Gut Liver. 2017; 11(6):870-877.

PMID: 28750484 PMC: 5669604. DOI: 10.5009/gnl16434.


Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.

Wiegand S, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Boker K PLoS One. 2015; 10(12):e0145622.

PMID: 26699619 PMC: 4689517. DOI: 10.1371/journal.pone.0145622.


Role of occult hepatitis B virus infection in chronic hepatitis C.

Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S World J Gastroenterol. 2015; 21(42):11931-40.

PMID: 26576082 PMC: 4641115. DOI: 10.3748/wjg.v21.i42.11931.